We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 13

Researchers highlight appeal of gene editing techniques
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2014

A recent Trends in Biotechnology review highlighting "genetically edited organisms" (GeOs) has reportedly suggested that new techniques designed to


Newlink Genetics sets IPO estimates
  • Shook Hardy & Bacon LLP
  • USA
  • November 3 2011

NewLink Genetics Corp., an Iowa biopharmaceutical company focusing on immunotherapeutic products for improved cancer treatment options, has reportedly established the expected range of its initial public offering (IPO) of 5.5 million shares at $10 to $12 a share.


Parties to gene patent dispute change course by seeking U.S. Supreme Court review
  • Shook Hardy & Bacon LLP
  • USA
  • October 20 2011

After filing petitions for rehearing before the Federal Circuit Court of Appeals panel that split over whether genetic discoveries can be patented, the parties have apparently changed course and indicated their intent to petition the U.S. Supreme Court for review.


Court dismisses action to correct inventorship of two patents
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

A federal court in Massachusetts has determined that genetic researchers could neither substitute themselves as the inventors of two patents nor correct the patents' inventorship to add their names under 35 U.S.C. 256, because they had not engaged in any collaborative efforts with the named inventors.


Gene sequencing is king in scientific research and biotech startups
  • Shook Hardy & Bacon LLP
  • USA
  • March 24 2011

Academic interest in gene sequencing is reportedly leading growth in scientific research disciplines, and the technology is apparently driving biotech investment.


Research institution creates regional biomedical hub in Florida
  • Shook Hardy & Bacon LLP
  • USA
  • March 10 2011

The Jackson Laboratory, a Maine-based biomedical research institution, has announced a partnership to develop "genetics-based" treatments for heart disease, Alzheimer's disease and diabetes at a new 120,000-square-foot research facility in Sarasota County, Florida.


Biomedicine startup launches in Cambridge, Massachusetts
  • Shook Hardy & Bacon LLP
  • USA
  • February 7 2011

Japanese pharmaceutical company Eisai has reportedly invested up to $200 million for research and development in a Cambridge, Massachusetts-based biotech startup devoted to developing the next generation of cancer treatments.


Three-year collaboration to create synthetic seed virus bank for influenza shot
  • Shook Hardy & Bacon LLP
  • USA
  • October 21 2010

Novartis AG and Synthetic Genomics Vaccines, Inc. have apparently agreed to collaborate on a project that is intended to reduce the time needed to develop influenza vaccines.


Legislation grapples with bioengineered animals
  • Shook Hardy & Bacon LLP
  • USA
  • October 15 2010

U.S. Representative Rosa DeLauro (D-Conn.) has introduced a bill (H.R. 6325) that would require labeling for food that contains genetically engineered (GE) animal products.


Animal study links dietary phosphate to accelerated aging
  • Shook Hardy & Bacon LLP
  • USA
  • April 30 2010

A recent study has reportedly linked "dietary and genetic evidence for phosphate toxicity" to premature aging in genetically engineered (GE) mice.